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Abstract
Background: Previous studies have developed models predicting methylation age from DNA methylation in blood
and other tissues (epigenetic clock) and suggested the difference between DNA methylation and chronological ages
as a marker of healthy aging. The goal of this study was to confirm and expand such observations by investigating
whether different concepts of the epigenetic clocks in a population-based cohort are associated with cancer,
cardiovascular, and all-cause mortality.
Results: DNA methylation age was estimated in a cohort of 1863 older people, and the difference between age
predicted by DNA methylation and chronological age (Δage) was calculated. A case-cohort design and weighted
proportional Cox hazard models were used to estimate associations of Δage with cancer, cardiovascular, and all-cause
mortality. Hazard ratios for Δage (per 5 years) calculated using the epigenetic clock developed by Horvath were 1.23
(95 % CI 1.10–1.38) for all-cause mortality, 1.22 (95 % CI 1.03–1.45) for cancer mortality, and 1.19 (95 % CI 0.98–1.43) for
cardiovascular mortality after adjustment for batch effects, age, sex, educational level, history of chronic diseases,
hypertension, smoking status, body mass index, and leucocyte distribution. Associations were similar but weaker for
Δage calculated using the epigenetic clock developed by Hannum.
Conclusions: These results show that age acceleration in terms of the difference between age predicted by DNA
methylation and chronological age is an independent predictor of all-cause and cause-specific mortality and may be
useful as a general marker of healthy aging.
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Background
DNA methylation is a form of epigenetic control in-
volved in several cellular processes and in the regulation
of gene expression, especially through gene silencing [1].
Modifications of DNA methylation are influenced by
genetic and environmental factors, including age, a
phenomenon called “epigenetic drift” [2]. Such age-
related modifications are bidirectional (they both show
an increase and a decrease in methylation, depending on
the sites), vary between individuals of the same age, and
differ across the genome [3].
Several models, also called “epigenetic clock,” have
been developed, predicting chronological age from DNA
methylation (DNAmage) with high accuracy [4, 5]. An
Italian study showed that semi-supercentenarians had a
lower epigenetic age than age-matched controls and that
their offspring’s epigenetic age was systematically lower
than their chronological age [6], suggesting that epigen-
etic processes play a role in healthy aging. An increasing
number of studies indicate that the discrepancy between
DNAmage and chronological age may be associated with
age-related diseases and mortality. A few studies
indicated that epigenetic age acceleration (i.e., predicted
methylation age exceeding chronological age) was sig-
nificantly associated with increased mortality risk [7–9],
frailty [10], and lower cognitive performance [11], in-
cluding neuropathological markers of Alzheimer’s
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disease [12]. Age acceleration was also observed in brain
tissues of people affected by Trisomy 21, who have a
well-known increased risk of developing Alzheimer’s
disease [13] and there is emerging evidence that blood
epigenetic age may predict cancer incidence [14] and
mortality [15].
This literature seems to suggest that age acceleration
in terms of the difference between age predicted by
DNA methylation and chronological age could be a use-
ful marker of healthy aging. However, in order to cor-
roborate such findings, it is of importance to replicate
the above results in different population-based cohorts
and, additionally, to explore whether epigenetic age
acceleration is also associated with other relevant age-
related outcomes, such as cardiovascular disease (CVD)
mortality.
We aimed to investigate whether the discrepancy be-
tween DNAmage as predicted by the models of Hannum
et al. [4] (hereinafter also DNAmage (Hannum)) and Horvath
[5] (hereinafter also DNAmage (Horvath)) and chronological
age is associated with cancer, cardiovascular, and all-cause
mortality in a population-based cohort of older people.
Methods
Study population and study design
Measurements of DNA methylation in blood were per-
formed in a baseline subsample of the ESTHER cohort,
which is a large population-based epidemiological study
conducted in the German State of Saarland with the aim
of assessing chances of prevention and early detection of
chronic diseases. As described in more detail in Saum et
al. [16], between July 2000 and December 2002, general
practitioners recruited 9949 older adults aged 50–
75 years during a regular health check-up.
Socio-demographic, lifestyle, and health characteristics
were collected using standardized self-administered
questionnaires. Self-reported diagnoses of prevalent car-
diovascular diseases, cancer, hypertension, and diabetes
mellitus were validated through medical records. Infor-
mation on survival status was obtained by record linkage
with population registries. Cause of death was ascer-
tained according to death certificate. All participants
provided blood samples, which were stored at −80 °C.
The Ethics Committee of the Medical Faculty of the
University of Heidelberg and of the Physician Board of
Saarland approved the study and participation was con-
ditional on written informed consent.
Due to financial constraints, DNA was extracted only
from a subsample of 3499 ESTHER participants who
were recruited in the initial phase of the enrolment be-
tween July 2000 and March 2001 and who therefore had
the longest follow-up time. Among these, epigenetic
measurements were conducted in a randomly selected
subcohort of 1548 participants irrespective of survival
status as well as in all participants who had died during
follow-up (cases) and did not overlap with the randomly
selected subcohort (N = 316). In total, 1864 participants
with epigenetic measurements were therefore available
for the present case-cohort study.
DNA methylation measurement
Blood DNA was extracted using a salting out procedure
[17] and measured using PicoGreen (Invitrogen, Darmstadt,
Germany). DNA methylation profiles were measured using
the Infinium HumanMethylation450 BeadChip (Illumina
Inc.) in the Genomics and Proteomics Core Facility at the
German Cancer Research Center, Heidelberg. As quality
control, three random DNA samples for each plate were
used as duplicates for replication. Methylation levels at each
CpG were calculated with Illumina’s Genomestudio
2011.1, Modul M Version 1.9.0 as previously de-
scribed in detail [18].
Prediction of DNAmage
DNAmage (Horvath) was calculated using the R tutorial of
the pertinent publication [5] and DNAmage (Hannum) as
the sum of the beta values multiplied by the respective
regression coefficients reported by Hannum et al. [4] as
already described by Marioni et al. [7]. For all calcula-
tions of DNAmage, we only used signals of probes with a
detection p value ≤0.05.
Statistical analysis
We used descriptive statistics to show the distribution of
socio-demographic variables and prevalent diseases at
baseline separately among the participants of the ran-
domly selected subcohort who survived over the follow-
up and among the cases. We also differentiated the cases
between those participants of the subcohort who de-
ceased during the follow-up (cases within the subcohort)
and those who were specifically selected among de-
ceased participants (cases outside the subcohort).
Following Marioni et al. [7], we calculated the differ-
ence between age predicted by DNA methylation and
chronological age (Δage; epigenetic age acceleration) and
estimated hazard ratios (HR) for the association of Δage
(per 5 years of age acceleration) with all-cause and
cause-specific mortality. HRs were estimated using the
SAS® program code implementing weighted proportional
Cox hazard models as illustrated in detail by Kulathinal
and colleagues [19]. Effect estimates were adjusted in
model 1 for batch effects, chronological age (continuous),
sex, and leucocyte distribution including the following cell
types: CD56 natural killer cells, CD14 monocytes,
CD4 T-cells, CD8 T-cells, CD19 B-cells, and granulo-
cytes. Proportions of leucocyte cells were estimated
from DNA methylation using the algorithm from
Houseman et al. [20]. Model 2 was additionally
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adjusted for educational level, history of cancer, his-
tory of CVD, hypertension, diabetes mellitus, smoking
status, and body mass index. Sensitivity analyses were
conducted without adding leucocyte distribution as a
covariate in model 1.
Scatter plots were generated in order to illustrate the
relationship between chronological age and DNAmage.
Pearson correlation coefficient (r) between chronological
and methylation age were calculated both for DNAmage
(Horvath) and DNAmage (Hannum).
In order to explore specific biological components of
the epigenetic clock associated with mortality, we esti-
mated, in Cox models adjusted for chronological age,
sex, leucocyte distribution, and batch effects, which of
the 353 CpGs of Horvath’s epigenetic clock were signifi-
cantly associated with all-cause mortality. Multiple test-
ing adjustments were performed both by controlling the
false discovery rate (FDR) and using the Bonferroni
correction.
With the exception of DNAmage (Horvath), which we
calculated using R software version 3.1.1, we conducted
all analyses using SAS® statistical software version 9.4
(SAS® Institute Inc., Cary, NC, USA).
Results
The subsample of the ESTHER cohort consisted of 1863
participants with 1260 (67.6 %) survivors and 602
(32.3 %) cases (316 selected cases and 286 deceased par-
ticipants within the subcohort) and 1 participant with
missing information relating to survival status (Table 1).
Overall, we recorded 235 (12.6 %) deaths due to cancer
(N = 95 among women and N = 140 among men) and
194 (10.4 %) cardiovascular deaths (N = 80 among
women and N = 114 among men). The majority of de-
ceased participants were men both among cases outside
the subcohort (56.3 %) and within the subcohort
(60.5 %). Cases showed more age-related diseases at
baseline, such as CVD, hypertension, and diabetes melli-
tus, than survivors. Also, there were more current
smokers among cases within (27.0 %) and outside
(24.3 %) the subcohort than among surviving partici-
pants (16.4 %).
Mean chronological age at baseline in the total study
population was 62.5 (SD 6.6; min 48.0, max 75.0). Mean
of DNAmage (Horvath) was 63.0 (SD = 7.5; min = 38.9 max
95.7) and mean of DNAmage (Hannum) was 68.6 (SD = 7.1;
min = 47.1 max 95.9). Pearson correlation coefficient
between chronological and methylation age was 0.73
(p < 0.0001) for DNAmage (Horvath) and 0.77 (p < 0.0001)
for DNAmage (Hannum). Panels a and b of Fig. 1 display
scatter plots showing the relationship between chrono-
logical and DNAmage both among deceased participants
(red circles) and those alive at last follow-up (black cir-
cles). Also, there was a strong linear relationship between
DNAmage (Horvath) and DNAmage (Hannum) (r = 0.80; p <
0.0001).
Weighted proportional Cox hazard models revealed that
irrespective of which predictor was used, a DNA methyla-
tion age higher than chronological age was associated with
higher mortality. In Cox models adjusted for age, sex,
batch effects, and leucocyte distribution HRs for the asso-
ciation of Δage (per 5 years) with all-cause mortality
showed a statistically significant increase in mortality by
22 % using DNAmage (Horvath) and an increase in mortality
by 16 % using DNAmage (Hannum) (Table 2). In the fully
Table 1 Distribution of socio-demographic variables and
prevalent diseases at baseline among participants of the case
cohort (ESTHER study 2000–2001)





Female 721 (57.2) 113 (39.5) 138 (43.7)
Men 539 (42.8) 173 (60.5) 178 (56.3)
Age
50–65 905 (71.8) 123 (43.0) 163 (51.6)
66–75 355 (28.2) 163 (57.0) 153 (48.4)
Years of school education
>9 years 334 (27.0) 56 (20.4) 63 (20.5)
≤9 years 902 (73.0) 218 (80.6) 244 (79.5)
History of cancer disease
No 1201 (95.3) 254 (88.8) 268 (84.8)
Yes 59 (4.7) 32 (11.1) 48 (15.2)
History of cardiovascular
disease
No 1048 (83.2) 171 (59.8) 206 (65.2)
Yes 212 (16.8) 115 (40.2) 110 (34.8)
Hypertension
No 714 (56.7) 142 (50.5) 154 (49.2)
Yes 545 (43.3) 139 (49.5) 159 (50.8)
Diabetes mellitus
No 1068 (85.9) 216 (76.1) 227 (73.0)
Yes 176 (14.2) 68 (23.9) 84 (27.0)
Body mass index (kg/m2)
<25 341 (27.1) 79 (27.6) 97 (30.7)
25–<30 594 (47.1) 124 (43.4) 132 (41.8)
≥30 325 (25.8) 83 (29.0) 87 (27.5)
Smoking
Never/former 1034 (83.6) 203 (73.0) 233 (75.7)
Current 203 (16.4) 75 (27.0) 75 (24.3)
aParticipants of the randomly selected subcohort who were deceased during
the follow-up (2000–2013)
bParticipants specifically selected among deceased participants
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adjusted models, HR estimates for Δage were stronger for
DNAmage (Horvath) (HR = 1.23; 95 % CI 1.10–1.38) than for
DNAmage (Hannum), which were no longer statistically sig-
nificant (HR = 1.10; 95 % CI 0.94–1.29).
Epigenetic age acceleration was also associated with
higher cancer and CVD mortality in Cox models using
Horvath’s predictor and adjusted for age, sex, batch
effects, and leucocyte distribution (HR = 1.20; 95 % CI
1.03–1.39 and HR = 1.20; 95 % CI 1.02–1.42, respect-
ively). Cox models for DNAmage (Hannum) also showed an
increased mortality both for cancer and CVD mortality
in partially adjusted models but estimates were weaker
and they were not statistically significant (HR = 1.08;
95 % CI 0.87–1.35 and HR = 1.13; 95 % CI 0.89–1.44,
respectively).
Associations of epigenetic age acceleration with all-
cause and cause-specific mortality were very similar
among women and men (Table 3).
Sensitivity analyses conducted without adding leucocyte
distribution as covariate in model 1 revealed weaker point
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Fig. 1 a Relationship between DNA methylation age estimated with Hannum’s predictor and chronological age. b Relationship between DNA
methylation age estimated with Horvath’s predictor and chronological age
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estimates for DNAmage (Horvath) (HR(all-cause mortality) = 1.17;
95 % CI 1.06–1.30; HR (cancer mortality) = 1.15; 95 % CI 0.99–
1.34; HR(CVD mortality) = 1.15; 95 % CI 0.98–1.34) and stron-
ger estimates for DNAmage (Hannum) (HR(all-cause mortality) =
1.21; 95 % CI 1.06–1.38; HR (cancer mortality) = 1.11; 95 % CI
0.91–1.37; HR(CVD mortality) = 1.20; 95 % CI 0.96–1.50) .
Cox regression analyses for the 353 CpGs of Horvath’s
epigenetic clock revealed that 6 CpGs (cg19724470 in
CD27; cg15804973 in MAP3K5, cg25564800 in KPNA1;
cg01820374 in LAG3; cg01511567 in SSRP1; cg26614073
in SCAP) showed a statistically significant association
with mortality after FDR adjustment and 3 CpGs after
Bonferroni correction (Additional file 1: Table S1). With-
out adjustment for multiple testing, we found that 33
CpGs were associated with mortality.
Discussion
In this cohort of older adults, epigenetic age acceleration
in terms of the difference between methylation age and
chronological age was associated with increased total,
cancer, and CVD mortality even after adjustment for a
large number of potential confounders. These findings
strengthen suggestions that epigenetic age acceleration
may be a general (bio-)marker of healthy aging.
Being the first study addressing CVD mortality, we
cannot compare our results relating to such outcome
with other studies, but our findings relating to all-cause
mortality were quite comparable with those from a re-
cent publication. In particular, Marioni and colleagues
[7] found that Δage (per 5 years) was significantly
associated with a 21 % greater mortality risk in a
model adjusted for chronological age and sex using
DNAmage (Hannum) (HR = 1.21; 95 % CI 1.14–1.29) and
with a 11 % increase using DNAmage (Horvath) (1.11; 95 %
CI 1.05–1.18). The consistent results obtained for all-
Table 2 Associations of differences between Δage (per 5 years)
according to different predictors of DNAmage with all-cause and
cause-specific mortality
Causes of death
(N of events; %)






(602; 32.3) DNAmage (Horvath) 1.22 (1.10–1.36) 1.23 (1.10–1.38)
(602; 32.3) DNAmage (Hannum) 1.16 (1.00–1.34)* 1.10 (0.94–1.29)
Cancer mortality
(235; 12.6) DNAmage (Horvath) 1.20 (1.03–1.39) 1.22 (1.03–1.45)
(235; 12.6) DNAmage (Hannum) 1.08 (0.87–1.35) 1.03 (0.80–1.33)
Cardiovascular
disease mortality
(194; 10.4) DNAmage (Horvath) 1.20 (1.02–1.42) 1.19 (0.98–1.43)
(194; 10.4) DNAmage (Hannum) 1.13 (0.89–1.44) 1.00 (0.79–1.29)
*p = 0.0408
aModel 1: adjusted for chronological age (continuous), sex, batch effects, and
leucocyte distribution
bModel 2: additionally adjusted for educational level, history of cancer
diseases, history of CVD, hypertension, diabetes mellitus, smoking status
(never/former vs. current), and body mass index (continuous)
Table 3 Associations of differences between Δage (per 5 years) according to different predictors of DNAmage with all-cause and
cause-specific mortality by sex





Women 251; 41.7 DNAmage (Horvath) 1.27 (1.07–1.52) 1.24 (1.02–1.52)
DNAmage (Hannum) 1.19 (0.94–1.51) 1.05 (0.82–1.36)
Men 351; 58.3 DNAmage (Horvath) 1.23 (1.05–1.43) 1.28 (1.09–1.51)
DNAmage (Hannum) 1.14 (0.94–1.40) 1.14 (0.92–1.41)
Cancer mortality
Women 95; 40.4 DNAmage (Horvath) 1.20 (0.93–1.54) 1.21 (0.88–1.65)
DNAmage (Hannum) 1.02 (0.69–1.50) 0.89 (0.58–1.36)
Men 140; 59.6 DNAmage (Horvath) 1.18 (0.95–1.47) 1.25 (0.98–1.59)
DNAmage (Hannum) 1.08 (0.80–1.46) 1.12 (0.79–1.58)
CVD mortality
Women 80; 41.2 DNAmage (Horvath) 1.17 (0.91–1.51) 1.13 (0.82–1.55)
DNAmage (Hannum) 1.21 (0.85–1.72) 1.01 (0.64–1.61)
Men 114; 58.8 DNAmage (Horvath) 1.25 (0.98–1.59) 1.29 (0.99–1.68)
DNAmage (Hannum) 1.06 (0.77–1.47) 1.00 (0.71–1.42)
CVD cardiovascular disease
aModel 1: adjusted for chronological age (continuous), sex, batch effects, and leucocyte distribution
bModel 2: additionally adjusted for educational level, history of cancer diseases, history of CVD, hypertension, diabetes mellitus, smoking status (never/former vs.
current), and Body Mass Index (continuous)
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cause mortality reinforce suggestions that epigenetic age
acceleration may be regarded as a possible candidate bio-
marker of healthy aging.
In our main analysis with adjustment for leucocyte dis-
tribution, the association between Δage and mortality was
stronger for DNAmage (Horvath) than for DNAmage (Hannum).
In sensitivity analyses without adjustment for leucocyte
distribution, point estimates for DNAmage (Hannum), but
not for DNAmage (Horvath), were stronger than the corre-
sponding point estimates adjusted for leukocyte distribu-
tion. This seems to suggest that Horvath’s predictor, being
developed from several human tissues and cell types and
not only from blood, might be more robust than the
blood-based predictor from Hannum and also less sensi-
tive to changes in blood cell composition, which could
mediate the association between Δage and mortality [7].
However, given that the direction of the association
remained stable and that there was only a moderate
change in the strength of the association for both predic-
tors, we can infer that leucocyte distribution did not have
a major influence on the association between epigenetic
clocks and mortality in our cohort.
Mean DNAmage predicted by the Hannum’s predictor
was approximately 6 years higher than mean chrono-
logical age, an overestimation also observed in the co-
horts analyzed by Marioni and colleagues [7]. Given the
very good correlation between methylation and chrono-
logical age and the strong linear relationship between
DNAmage (Horvath) and DNAmage (Hannum), we did not
deem it necessary to account for the overestimation.
Our findings indicating associations between Δage and
cancer mortality are in line with studies showing that
methylation changes might represent an early event in
the development of cancerous cells [2, 3] and be able to
predict cancer incidence [14, 15]. Our results suggest
that epigenetic age acceleration might also be an indica-
tor for a more aggressive course of tumor disease with
increased risk of a cancer-related fatal event, which sup-
ports the results of Zheng et al. [15] who also found that
the discrepancy between epigenetic and chronological
ages predicted cancer mortality.
Our findings revealing that epigenetic age acceleration
was also associated with a 20 % greater CVD mortality
risk (for estimates based on Horvath’s predictor) reveal a
magnitude of association comparable to the observed as-
sociation related to cancer mortality, even if CVD mor-
tality was less frequent than cancer mortality (194 vs
235, respectively) and therefore CVD mortality models
had less statistical power.
A possible explanation for the observed similar magni-
tude of association is that, similar to cancer, the develop-
ment of CVD also involves focal proliferative events [3,
21] and this might point to a relationship between aber-
rant methylation in older age and focal proliferation
processes. In particular, on the one hand, an abnormal
epigenetic drift might lead to an aggravation of focal
proliferative events leading, inter alia, to cardiovascular
and tumor diseases, and on the other hand, focal prolif-
erative events might lead to further abnormal epigenetic
drift [3] with exacerbation of the cardiovascular and can-
cer pathologies leading eventually to higher mortality.
The design of our study with epigenetic measurements
obtained several years prior to the event supports a role
of epigenetic changes leading to the exacerbation of can-
cer and CVD disease, but it cannot definitively exclude
reciprocal influences, as the event leading to greater
mortality might have already affected the epigenetic sta-
tus at an early stage of the disease and be reflected in
the epigenetic measurements.
Lin and colleagues [9] tested associations of single
CpG-derived age predictions with mortality in the
LBC1936 cohort. Two CpGs that showed significant re-
sults before adjustment for multiple testing were over-
lapping with our findings (cg19724470 and cg15804973).
Further studies should explore biological properties of
such genes and the possible pathways leading to early
mortality.
Strengths of our study were analyses conducted with
two different predictors, the large and representative
sample size, and adjustment for important confounders;
main limitations were the lack of differential blood
counts and the impossibility to ascertain in our popula-
tion the exact temporal relationship between epigenetic
age acceleration and focal proliferative events.
Conclusions
In conclusion, our study further confirms the validity of
estimates of DNAmage based on Horvath’s and Hannum’s
epigenetic clocks, it expands previous observations by in-
cluding CVD mortality, and it indicates that epigenetic
age acceleration might be both a useful marker of healthy
aging among older people as well as a prognostic marker.
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